Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
CLINIMIX E 5/10 SULFITE FREE W/ ELECT IN DEXTROSE 10% W/ CALCIUM IN PLASTIC CONTAINER vs AMINESS 5.2% ESSENTIAL AMINO ACIDS W/ HISTADINE
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
CLINIMIX E 5/10 provides essential amino acids, electrolytes, and dextrose for parenteral nutrition, supporting protein synthesis and energy metabolism. Dextrose supplies glucose for cellular energy, while amino acids serve as substrates for protein synthesis. Electrolytes maintain acid-base balance and osmotic regulation.
Provides essential amino acids and histidine for protein synthesis in patients unable to tolerate oral or enteral nutrition, supporting nitrogen balance and tissue repair. The amino acids are utilized for anabolic processes and metabolic pathways.
Parenteral nutrition for adult and pediatric patients when oral or enteral nutrition is not possible or insufficient,Metabolic stress states such as trauma, sepsis, or burns (off-label use)
Treatment of uremic patients undergoing dialysis who require essential amino acid supplementation,Nutritional support in patients with renal insufficiency or failure where nonessential nitrogen sources are contraindicated
Intravenous infusion. Dosage is individualized based on patient's metabolic requirements, clinical condition, and laboratory parameters. Typical adult dose: 1.5-2 g amino acids/kg/day and 10-15 g dextrose/kg/day (max 5 mg/kg/min dextrose). Rate: Infuse via central line at ≤ 3 m L/kg/hr initially, titrate up to 100-125 m L/hr. Do not exceed 125 m L/hr.
Intravenous infusion: 500 m L of 5.2% solution (26 g amino acids) over 8-12 hours daily, providing 0.8-1.2 g/kg/day of amino acids depending on metabolic needs.
Amino acids: variable, ~1-2 hours for most, reflecting rapid metabolism and utilization. Dextrose: not applicable as endogenous molecule; infusion half-life ~15-30 minutes due to insulin-mediated clearance. Clinical context: renal impairment prolongs amino acid elimination.
Approximately 2-4 hours for most essential amino acids; clinical context: rapid clearance necessitates continuous infusion for stable plasma levels.
Amino acids undergo deamination and transamination in the liver; dextrose is metabolized via glycolysis and the citric acid cycle; electrolytes are excreted or reabsorbed by the kidneys.
Amino acids are metabolized via transamination, deamination, and incorporation into proteins. Hepatic and renal pathways involved in nitrogen disposal and urea cycle.
Amino acids and electrolytes are primarily excreted renally. Dextrose is metabolized to CO2 and water, exhaled via lungs. Unmetabolized dextrose excreted renally if threshold exceeded. Less than 5% biliary/fecal.
Renal: >95% as amino acids and metabolites; negligible biliary/fecal.
Amino acids: minimal (<10%), mainly to albumin. Dextrose: not bound. Electrolytes: variably bound (e.g., calcium ~40% to albumin).
Minimal (<10%) for most amino acids; not significantly protein-bound.
Amino acids: ~0.5-1 L/kg, reflecting distribution to total body water. Dextrose: ~0.2-0.3 L/kg (extracellular). Electrolytes: Vd varies (e.g., calcium ~0.5 L/kg).
Approximately 0.2-0.4 L/kg total body water; reflects distribution primarily into extracellular fluid.
Intravenous: 100%.
Intravenous: 100%.
GFR > 50 m L/min: no adjustment. GFR 30-50 m L/min: reduce amino acid dose to 0.5-1 g/kg/day. GFR 15-29 m L/min: 0.5-0.8 g/kg/day. GFR < 15 m L/min (not on dialysis): restrict to 0.4-0.6 g/kg/day. Monitor electrolytes closely.
For GFR < 30 m L/min: reduce dose to 0.5-0.8 g/kg/day; for GFR < 15 m L/min: 0.3-0.5 g/kg/day; avoid if severe untreated uremia.
Child-Pugh A: usual dose. Child-Pugh B: reduce amino acid dose by 25-50% and monitor ammonia levels. Child-Pugh C: avoid or use with extreme caution; use specially formulated solutions (e.g., branched-chain amino acid enriched).
Child-Pugh A: no adjustment; Child-Pugh B: reduce dose by 25-50%; Child-Pugh C: contraindicated due to risk of hepatic encephalopathy.
Intravenous infusion. Neonates: 1.5-3 g amino acids/kg/day, dextrose 4-8 mg/kg/min. Infants: 2-3 g amino acids/kg/day, dextrose 10-15 mg/kg/min. Children: 1.5-2 g amino acids/kg/day, dextrose 5-10 mg/kg/min. Rate adjusted per tolerance and fluid requirements.
Infants and children: 1-2 g/kg/day as continuous infusion; neonates: 0.5-1 g/kg/day, titrated to metabolic response.
Elderly patients may have reduced renal function; start at lower end of dosing range (e.g., 1.0-1.5 g amino acids/kg/day and 5-10 g dextrose/kg/day). Monitor glucose, electrolytes, and renal function closely. Adjust rate to avoid fluid overload.
Start at 0.6-0.8 g/kg/day; monitor renal function and protein tolerance; adjust for comorbidities like renal impairment or heart failure.
This product contains aluminum that may be toxic. Patients with impaired kidney function, including premature neonates, may accumulate aluminum at levels associated with CNS and bone toxicity.
Not for intravenous infusion. For oral or enteral use only. Do not administer parenterally.
Monitor serum glucose, electrolytes, and acid-base status; risk of hyperglycemia, electrolyte imbalances, and metabolic acidosis; use caution in renal or hepatic impairment; aluminum toxicity risk with prolonged use.
Monitor serum electrolytes, BUN, and ammonia levels; risk of hyperammonemia in hepatic impairment,Use with caution in patients with metabolic acidosis or fluid overload,May cause gastrointestinal intolerance; adjust rate of administration
Hypersensitivity to any component, severe hyperglycemia, uncontrolled metabolic acidosis, severe electrolyte disturbances, and acute pulmonary edema or cardiac decompensation.
Hypersensitivity to any component,Phenylketonuria (contains phenylalanine),Severe hepatic failure with hyperammonemia
No oral food or enteral feedings while receiving this parenteral nutrition unless specifically prescribed. Avoid alcohol, which can worsen electrolyte imbalances or liver stress. Some components may interact with anticoagulants (e.g., vitamin K in amino acids) but no specific food restrictions.
No specific food interactions. Patients should follow prescribed dietary protein restrictions if indicated (e.g., in hepatic encephalopathy). Avoid alcohol as it may worsen liver function.
CLINIMIX E 5/10 SULFITE FREE W/ ELECT IN DEXTROSE 10% W/ CALCIUM IN PLASTIC CONTAINER is a parenteral nutrition solution. Dextrose and electrolytes are essential nutrients; no teratogenic risk is expected with appropriate use. However, calcium gluconate may cause fetal hypocalcemia if maternal levels are imbalanced. First trimester: no known teratogenicity. Second trimester: metabolic disturbances may occur if maternal homeostasis is disrupted. Third trimester: risk of neonatal hypoglycemia if maternal glucose levels are high; risk of fetal hypercalcemia or hypocalcemia if calcium levels are abnormal.
Amino acid solutions like Aminess 5.2% are essential for fetal development. No teratogenic effects reported; however, use only if clearly needed as maternal nutritional status directly impacts fetal outcomes.
Dextrose, amino acids, and electrolytes are endogenous and normally present in breast milk. Calcium is secreted into milk; maternal supplementation may increase milk calcium concentration. No specific M/P ratio is available. Use with caution; monitor infant for gastrointestinal effects. Compatible with breastfeeding when used as directed.
No data available on milk concentrations. Essential amino acids are normal components of breast milk. Use with caution; benefits likely outweigh risks in malnourished mothers.
Pregnancy increases plasma volume and renal blood flow, potentially altering electrolyte requirements and clearance. Dose adjustments may be needed for calcium and magnesium due to increased maternal demand and protein binding changes. Glucose metabolism is altered; monitor glucose tolerance and adjust dextrose infusion rate to avoid hyperglycemia. No specific dose adjustment guidelines exist; individualize based on clinical monitoring.
Pregnancy increases plasma volume and glomerular filtration rate, potentially altering pharmacokinetics. Monitor clinical response and consider dose adjustments based on metabolic demands; no specific dose adjustment guidelines available.
CLINIMIX E 5/10 is a dual-chamber bag containing amino acids with electrolytes and dextrose. Do not use if the bag has been frozen or if the solution is discolored or contains particulates. Invert the bag to mix the contents thoroughly before administration. Do not administer simultaneously with blood through the same infusion set due to risk of pseudogglutination. Monitor serum glucose, electrolytes, and fluid balance closely, especially in patients with renal impairment, diabetes, or fluid overload. Use a dedicated line or a filter if required per protocol.
Monitor serum ammonia levels in patients with hepatic impairment as essential amino acids may exacerbate hyperammonemia. Use with caution in fluid-restricted patients due to high volume load. Ensure adequate non-protein calories to promote protein synthesis and prevent amino acid catabolism. Do not administer simultaneously with blood products via same IV line.
This medication is a sterile solution that provides nutrition and calories through a vein. It should only be administered by a healthcare professional.,Tell your doctor if you have kidney problems, diabetes, or fluid retention, as they may need to adjust the dosage.,Report any signs of infection at the IV site (redness, swelling, pain), fever, chills, or difficulty breathing.,Do not eat or drink anything unless instructed by your doctor, as this solution is meant to replace or supplement oral nutrition.,You may need regular blood tests to monitor your blood sugar, electrolyte levels, and kidney function.
This solution provides essential amino acids to support protein synthesis when you cannot eat enough protein.,It is given intravenously; report any burning, pain, or swelling at the IV site.,Your blood may be monitored for ammonia and electrolyte levels during treatment.,Inform your healthcare provider if you have liver disease, diabetes, or fluid restrictions.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about CLINIMIX E 5/10 SULFITE FREE W/ ELECT IN DEXTROSE 10% W/ CALCIUM IN PLASTIC CONTAINER vs AMINESS 5.2% ESSENTIAL AMINO ACIDS W/ HISTADINE, answered by our medical review team.
CLINIMIX E 5/10 SULFITE FREE W/ ELECT IN DEXTROSE 10% W/ CALCIUM IN PLASTIC CONTAINER is a Parenteral Nutrition Solution that works by CLINIMIX E 5/10 provides essential amino acids, electrolytes, and dextrose for parenteral nutrition, supporting protein synthesis and energy metabolism. Dextrose supplies glucose for cellular energy, while amino acids serve as substrates for protein synthesis. Electrolytes maintain acid-base balance and osmotic regulation.. AMINESS 5.2% ESSENTIAL AMINO ACIDS W/ HISTADINE is a Parenteral Nutrition Solution that works by Provides essential amino acids and histidine for protein synthesis in patients unable to tolerate oral or enteral nutrition, supporting nitrogen balance and tissue repair. The amino acids are utilized for anabolic processes and metabolic pathways.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between CLINIMIX E 5/10 SULFITE FREE W/ ELECT IN DEXTROSE 10% W/ CALCIUM IN PLASTIC CONTAINER and AMINESS 5.2% ESSENTIAL AMINO ACIDS W/ HISTADINE depend on the specific clinical indication. These are both Parenteral Nutrition Solution agents and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of CLINIMIX E 5/10 SULFITE FREE W/ ELECT IN DEXTROSE 10% W/ CALCIUM IN PLASTIC CONTAINER is: Intravenous infusion. Dosage is individualized based on patient's metabolic requirements, clinical condition, and laboratory parameters. Typical adult dose: 1.5-2 g amino acids/kg/day and 10-15 g dextrose/kg/day (max 5 mg/kg/min dextrose). Rate: Infuse via central line at ≤ 3 m L/kg/hr initially, titrate up to 100-125 m L/hr. Do not exceed 125 m L/hr.. The standard adult dose of AMINESS 5.2% ESSENTIAL AMINO ACIDS W/ HISTADINE is: Intravenous infusion: 500 m L of 5.2% solution (26 g amino acids) over 8-12 hours daily, providing 0.8-1.2 g/kg/day of amino acids depending on metabolic needs.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between CLINIMIX E 5/10 SULFITE FREE W/ ELECT IN DEXTROSE 10% W/ CALCIUM IN PLASTIC CONTAINER and AMINESS 5.2% ESSENTIAL AMINO ACIDS W/ HISTADINE in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. CLINIMIX E 5/10 SULFITE FREE W/ ELECT IN DEXTROSE 10% W/ CALCIUM IN PLASTIC CONTAINER is classified as Category C. CLINIMIX E 5/10 SULFITE FREE W/ ELECT IN DEXTROSE 10% W/ CALCIUM IN PLASTIC CONTAINER is a parenteral nutrition solution. Dextrose and electrolytes are essential nutrients; no tera. AMINESS 5.2% ESSENTIAL AMINO ACIDS W/ HISTADINE is classified as Category C. Amino acid solutions like Aminess 5.2% are essential for fetal development. No teratogenic effects reported; however, use only if clearly needed as maternal nutritional status dire. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.